KIT and non-small cell lung carcinoma: The mechanisms of acquired resistance to crizotinib in NSCLC include secondary mutations within the ALK kinase domain, amplification of the ALK gene, and bypass of important signalling mechanisms via an increase in EGFR phosphorylation or KIT amplification, and so on [23, 28, 38].